CORRECTION: Wedbush Maintains Neutral On Vera Therapeutics, Raises Price Target To $43

Vera Therapeutics, Inc. Class A

Vera Therapeutics, Inc. Class A

VERA

0.00

Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:VERA) with a Neutral and raises the price target from $35 to $43.